Search
Alabama Paid Clinical Trials
A listing of 1228 clinical trials in Alabama actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
157 - 168 of 1228
Alabama is currently home to 1228 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/27/2025
Locations: Southern Cancer Center, Daphne, Alabama
Conditions: Solid Tumors
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Recruiting
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Research Site, Fairhope, Alabama
Conditions: Cardiovascular Disease
Pivotal Study for the Cardiac Performance System (CPS)
Recruiting
This multi-center, observational study evaluates the accuracy of the Cardiac Performance System (CPS), a non-invasive device, for measuring hemodynamic parameters in adult patients undergoing clinically indicated right heart catheterization. The study compares CPS measurements to invasive measurements to assess agreement and potential clinical utility.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Huntsville Hospital Heart Center, Huntsville, Alabama
Conditions: Cardiovascular Diseases
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/26/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Telehealth Intervention to Increase Patient Preparedness for Surgery in Patients Undergoing Urogynecologic Surgery
Recruiting
There are 3 aims of this study. In Aim 1 community patient partners will be enrolled to help guide the research being performed in all of the aims. Investigators will also administer a survey that will help determine factors associated with surgical preparedness. In Aim 2 investigators will develop an intervention to increase surgical preparedness using Human Centered Design Methods. Aim 3 will pilot test the intervention using mixed methods to determine feasibility and implementation outcomes.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Alabama Birmginham, Birmingham, Alabama
Conditions: Incontinence, Prolapse
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Recruiting
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Advanced Solid Tumor
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Recruiting
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/26/2025
Locations: Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Non-cystic Fibrosis Bronchiectasis
Investigations of Reproductive Cancers in Women
Recruiting
The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.
Gender:
FEMALE
Ages:
Between 45 years and 100 years
Trial Updated:
06/26/2025
Locations: University of Alabama, Birmingham, Birmingham, Alabama
Conditions: Uterine Cancer
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Recruiting
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Alliance for Multispecialty Research, LLC ( Site 0027), Daphne, Alabama
Conditions: Hypercholesterolemia
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Recruiting
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure.
Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are:
* Vicadrostat and empagliflozin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama
Conditions: Heart Failure
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Recruiting
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Clearview Cancer Institute, Huntsville, Alabama
Conditions: Lung Cancer, Non-squamous, Non-small Cell
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Recruiting
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama
Conditions: Endometrial Cancer